

▶ Every 20 seconds someone has a lower extremity amputation due to diabetes

- Diabetes affects about 415 million people globally ⁴
 - Patients with diabetes have a lifetime risk of developing foot ulcers of up to 25% ⁵
 - Up to 76% of diabetic neuropathic ulcers remain unhealed at 12 weeks, and 69% at 20 weeks ⁶
 - Diabetes is associated with 25–90% of all amputations ⁷
 - Up to 68% of patients undergoing amputation due to the complications of diabetes die within 5 years ⁸
- Every year, more than a million people lose at least part of their leg due to the complications of diabetes

That's one patient every 20 seconds ⁴

Find out more at www.pulse-flow.net



Midshires House
Midshires Business Park
Aylesbury
Buckinghamshire
HP19 8HL UK
E: info@pulse-flow.net
T: +44 (0)1296 678596

Caution: Federal law restricts this to sale by or on the order of a physician

• References

1. de Oliveira AL, Moore Z (2015) Treatment of the diabetic foot by offloading: a systematic review. *J Wound Care* 24(12):560-70
2. Mohamed FA, Bahey El-Deen HA (2015) Effect of Intermittent Pneumatic Compression Therapy on Healing of Diabetic Foot Ulcer. *International Journal of Diabetes Research* 4(4): 67-72
3. PulseFlowDF User Manual P8004/09
4. International Diabetes Federation (2015) *IDF Diabetes Atlas*. Seventh edition.
5. Singh N, Armstrong DG, Lipsky BA (2005) Preventing foot ulcers in patients with diabetes. *JAMA* 293: 217-28
6. Margolis DJ, Kantor J, Berlin JA (1999) Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. *Diabetes Care* 22(5):692-5
7. LEA Study Group (2000) Epidemiology of lower extremity amputations in centres in Europe, North America and East Asia. *Br J Surg* 87:328-37
8. Armstrong DG, Lavery LA, Harkless LB (1998) Validation of a diabetic wound classification system: The contribution of depth, infection, and ischemia to risk of amputation. *Diabetes Care* 21(5):855-9
9. Armstrong DG, Wrobel J, Robbins JM (2007) Guest editorial: are diabetes-related wounds and amputations worse than cancer? *Int Wound J*, 4: 286-7

Document No. PFTMCC001. Rev Date 1/2016

▶ Dual-action wearable technology for the treatment of diabetic foot ulcers



PulseFlowDF™
Protection. Pulsation. Performance.

- PulseFlowDF utilises cutting-edge wearable technology to combine two proven treatment strategies - offloading¹ and intermittent pneumatic compression² - to optimise wound healing in the diabetic foot.

This innovative Class II medical device features a biomechanically active but unobtrusive design and state-of-the-art construction materials to simultaneously increase blood flow, offload the wound and protect the foot from further injury³.

Built-in monitoring software ensures accurate treatment data capture and optimal patient engagement with treatment.



- “Being able to review wear time using the software was invaluable [as] there was a suspicion patients were not wearing the offloading devices. It was possible to show participants how little they had used the device and to reiterate the need to use it.”

Mr Richard Leigh
Head of Podiatry
Royal Free London Hospitals NHS Foundation Trust

- “PulseFlowDF produced statistically significant increases in both oxygenation and flow of venous blood from the foot.”

Professor Alexander M. Seifalian
Division of Surgery and Interventional Science
University College London

- “[PulseFlowDF] is the most important thing going on in this area of massive unmet medical need... it’s going to make a very big difference in the lives of people with diabetes.”

Professor David Armstrong
Division of Surgery and Interventional Science
University College London



PulseFlowDF™